Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

NCT01143402 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

NIH

Sponsor class

Conditions

Iris Melanoma
Medium/Large Size Posterior Uveal Melanoma
Ocular Melanoma With Extraocular Extension
Recurrent Uveal Melanoma
Small Size Posterior Uveal Melanoma
Stage IV Uveal Melanoma

Interventions

DRUG: Dacarbazine
OTHER: Laboratory Biomarker Analysis
OTHER: Quality-of-Life Assessment
DRUG: Selumetinib
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)